Abstract: Positron emission tomography (PET) gives an opportunity to quantitate the expression of specific molecular targets in vivo and longitudinally in brain and thus enhances our possibilities to understand and follow up multiple sclerosis (MS)-related pathology. For successful PET imaging, one needs a relevant target molecule within the brain, to which a blood-brain barrier-penetrating specific radioligand will bind. 18-kDa translocator protein (TSPO)-binding radioligands have been used to detect activated microglial cells at different stages of MS, and remyelination has been measured using amyloid PET. Several PET ligands for the detection of other inflammatory targets, besides TSPO, have been developed but not yet been used for imaging MS patients. Finally, synaptic density evaluation has been successfully tested in human subjects and gives opportunities for the evaluation of the development of cortical and deep gray matter pathology in MS. This review will discuss PET imaging modalities relevant for MS today.
Introduction
The diagnosis and follow-up of multiple sclerosis (MS) is mostly based on conventional magnetic resonance imaging (MRI) including T2-weighted, T1-weighted, and post-gadolinium T1-weighted images. 1, 2 The technique is, however, unspecific and unable to fully differentiate between abnormalities such as inflammation, demyelination, ischemia, and neural damage. 3 Thus, more specific in vivo molecular imaging techniques are needed for better understanding of the disease pathology.
Positron emission tomography (PET) imaging enables targeted, quantitative, and non-invasive imaging of physiological and pathological processes in vivo. The technique is based on radiolabeled ligands which accumulate into target tissues and structures. The radiolabels are radioisotopes with short half-life, such as 11 C, 15 O, and 18 F. The ligands on the other hand are molecules which bind specific targets expressed during processes of interest. The hallmarks of MS pathology and thus the processes in focus are inflammation, gliosis, demyelination, and degeneration. Using PET techniques, it is possible to image the heterogeneity of the MS lesions and inflammatory changes in normal-appearing white matter (NAWM) and gray matter (GM), but also functional changes of the brain. Brain PET imaging in MS has focused on imaging the reactive immune cells of the brain-resident innate immune system, that is, the microglia and macrophages. Other targets for MS-relevant PET imaging include reactive astrocytes, neurons, and myelin. In this review, we discuss the present status of ligand development and the practical experience in imaging of the various MS-relevant targets.
Microglia as an imaging target
Microglia are resident immune cells of the central nervous system (CNS). They are very much like peripheral macrophages as they are motile and capable of phagocytosis, and of secreting cytokines, chemokines, free radicals, and neurotrophic factors. 4 Microglia have two important functions in the CNS: defense and maintenance. As part of the innate immune system, they take care of the immune defense of the CNS. They also maintain homeostasis by contributing to neuronal proliferation and differentiation, and modulation of synaptic connections. 5 microglia are actively gathering information about their microenvironment and can thus be considered rather as surveying than resting. 6 Change in the homeostasis of CNS causes resting microglia to be activated. Previously, the distinction of microglia between resting and activated was considered as on-off situation. However, this process seems more complex and dependent on the activation mechanism. Classically activated or proinflammatory microglia (M1-like) are activated by interferon γ, and they secrete reactive oxygen species (ROS) and inflammatory cytokines. 7 Alternatively activated or anti-inflammatory microglia (M2-like) are divided to three subclasses (M2a, M2b, and M2c) according to their function and molecules stimulating the activation. 8 Microglial activity is induced in several neurodegenerative pathologies including MS, Alzheimer's (AD), and Parkinson's diseases (PD), and amyotrophic lateral sclerosis (ALS). Thus, it has become a major target of PET brain imaging of neuroinflammation and neurodegeneration.
18-kDa translocator protein
Most of the PET studies on MS have focused on imaging activated microglia using the 18-kDa translocator protein (TSPO) as a target. TSPO is a protein expressed on the outer membrane of mitochondria of activated microglia, and its high expression is linked to neuroinflammation and neuronal injury. 9 Recent evidence from in vitro and animal studies also indicates that the increased expression of TSPO in neuroinflammation might be specific for proinflammatory M1-like microglia. 10 TSPO expression has however, also been described in macrophages and in some astrocytes. 11 The oldest TSPO ligand is [ 11 13 this has been investigated in detail, but similar differences in the binding affinity between subjects have been observed for all second-and thirdgeneration TSPO ligands. The sensitivity of only one second-generation tracer, namely, [ 11 C]ER176, has been shown to be sufficient enough for the quantification of all three binding affinity types. 14 For all other tracers, low-affinity binders have too low specific radioligand binding to allow reliable quantification.
Despite the challenges, TSPO imaging has provided valuable information about microglial activation in MS in vivo. Using [ 11 C]PK11195, investigators have demonstrated that microglial activation is not only increased in MRI-detected focal inflammatory lesions in MS patients with active disease, but also in the NAWM and at the rim of chronic active lesions in patients with secondary progressive multiple sclerosis (SPMS), compared to relapsing-remitting multiple sclerosis (RRMS) and healthy controls. Importantly, the level of TSPO binding correlates with clinical disability. 15, 16 Figure 1 demonstrates the TSPO binding patterns related to demyelination in an MS patient. We have recently reviewed TSPO imaging in detail in this journal and elsewhere. 18, 19 Cannabinoid receptor CB2 Cannabinoid receptors are G-protein-coupled receptors of two subtypes, cannabinoid receptor 1 (CB1) which is mainly expressed in the CNS and cannabinoid receptor 2 (CB2) which is found particularly in the immune system, but also in certain parts of the CNS. 20 CB2 is expressed in neurons and microglia, and the expression is increased upon microglial activation. 21 There is growing evidence suggesting that CB2 receptor expression and activity contributes to the shift of M1-like microglia toward M2-like microglia. This makes CB2 an interesting and potential target of in vivo imaging of neuroinflammation. 22, 23 Interestingly, microglia themselves produce cannabinoid receptor ligand 2-arachidonoylglycerol (2-AG) in response to adenosine triphosphate (ATP) stimulation, 24,25 and the production has been linked to another receptor of interest, purinergic receptor P2X7, 25 discussed later in this review.
In MS, endocannabinoid system (ECS) is disrupted in multiple ways, and the expression of CB receptors, the production of endocannabinoids, and the expression of enzymes metabolizing them are altered. 20 The CB2 has been the main focus of interest as its levels are increased in neuroinflammation and during microglial activation while the expression level of CB1 is unaltered. The activity of CB1 has however been shown to reduce the severity of experimental autoimmune encephalomyelitis (EAE) in mice, which suggests a protective role for CBs. 20 Together with the recent report showing an early increase in CB2 following ischemia, 26 these findings suggest that CB2 expression might indicate an early stage of activation, or "primed" state of microglia. This might be related to an early neuroprotective response to injury. Altogether, the changes in ECS have made it a potentially interesting in vivo imaging target. To date, the most promising, and the only tracer tested in human subjects, is [ 11 C]NE40. 27, 28 The role of purinergic receptors during neuroinflammation The purinergic system includes a heterogenous group of purinergic receptors facilitating important signaling pathways of the nervous and immune system. 29 Extracellular purine and pyrimidine nucleosides and nucleotides, especially ATP, are important signaling molecules in the brain, and responsible for neuron-toneuron and neuron-to-glia communication. 30 ATP is a direct ligand of purinergic receptors, but its effects are also mediated through extracellular ecto-nucleotidases which produce extracellular adenosine diphosphate (ADP), adenosine monophosphate (AMP), and adenosine and thus control the ligand availability of nucleotide and adenosine receptors. 31,32 Nucleotides act through ionotropic (P2X) and metabotropic (P2Y) purinergic receptors, whereas adenosine activates G protein-coupled receptors adenosine A1 receptor (A1), adenosine A2A receptor (A2A), adenosine A2B receptor (A2B), and adenosine A3 receptor (A3). 33 Adenosine A2A receptor Among the four types of adenosine receptors, A2A signaling has particularly been described as a potent regulator of inflammation. 34 A2A receptors (A2ARs) are most abundant in the striatum, and in pathological conditions their expression has been demonstrated also in other CNS areas and cell types, such as microglia and astrocytes. 35 Most of all, A2AR has been shown to be involved in glial activation and neuroinflammation. 36 Development of several PET tracers (Table 1) have enabled imaging of A2AR and revealed its increased and spreading expression in neuroinflammatory and neurodegenerative diseases including MS. 36, 38 In AD, the astrocytic expression of A2AR has been recently shown, 35 but the identity and role of A2AR-expressing cells in MS remains to be seen. For further reading, we have recently reviewed imaging of A2AR in more detail elsewhere. 36 Purinergic P2X7 receptor (P2X7R) P2X7 receptors (P2X7R) are ATP-gated non-selective ion channels which are abundant in microglia, and they are also expressed in other glial cells such as astrocytes and oligodendrocytes. Neuronal expression of P2X7 has been somewhat controversial, 46, 47 but most of the evidence indicates its expression on presynaptic terminals. 29 The receptor activity in immune cells indicates a role for P2X7 in immune functions and inflammatory responses, and its activity has been shown to promote microglial activation and proliferation. 48 Most of all, the activity of P2X7 is a key event in the activation and recruitment of the inflammasome, 49 which is needed for processing and release of proinflammatory cytokines interleukin (IL)-1β and IL-18. 50 The interest in P2X7 as an imaging target for PET rises from its expression in microglia and increased activity during pathologies including neuroinflammation. 29 Recent reports indicate that P2X7 could be used in discriminating the proinflammatory M1-like microglia from M2-like microglia. 51 Increased expression of P2X7 in activated microglia has been reported in MS, 51, 52 although a recent study found that the P2X7 receptor is expressed yet inhibited in peripheral monocytes during acute phases of relapsing-remitting multiple sclerosis (RRMS). 53 This report further shows an increase in the expression of P2X7 in the astrocytes in the frontal cortex of SPMS patients. Several ligands targeting P2X7 have been evaluated preclinically (Table  2) but only a few have shown potential to proceed to studies in humans. 56, 60 The existence of multiple splice variants and genetic polymorphism of the P2X7 gene 62, 63 issue a challenge to research as some of them affect the function of the receptor, and thus may also lead to heterogeneity in binding potential of the tracer.
In addition, another purinergic receptor P2Y12 has been of interest as it is expressed particularly in resident M2-like microglia, and not in peripheral macrophages. 64 In line, its expression has been reported to be altered in pathologies such as AD, ALS, and MS. [65] [66] [67] However, more research is needed before P2Y12 can be considered as a valid PET imaging target.
Imaging myelin
Destruction of the myelin sheath wrapped around axons in the CNS is one of the hallmarks of MS. Remyelination can however restore the axonal function lost upon the demyelination process, and enhancing remyelination is a potential therapeutic approach. Hence, the ability to measure the remyelination process in vivo is of great interest both for designing therapeutic studies and for the evaluation of natural disease evolution. Thioflavin T derivatives (Pittsburgh Compound-B (PiB), flutemetamol, florbetabir, and florbetaben) are ligands that bind to fibrillar amyloid Aβ deposits and have mainly been used for the detection of cortical gray matter amyloid pathology in AD and related disorders. However, since these ligands also bind avidly to myelin in the white matter, with β amyloid precursor protein (APP) being the proposed binding site and playing a role in the processes of demyelination and remyelination, there has been growing interest for amyloid PET imaging in MS. 68 Indeed, the degree of demyelination in MS can be measured using [ 11 C]PiB showing not only decreased binding within demyelinated lesions, but also increasing binding with dynamic remyelination correlating to decreasing disability in follow-up. 69, 70 In addition, other promising PET tracers for myelin imaging have also been developed 71 and used in animal models of MS. Table 3 summarizes the key ligands and studies related to PET imaging of myelin in MS.
Imaging gray matter pathology-focus on neuronal synapses
Recent neuropathological studies have revealed over 50% reduction in synaptic density in both lesioned and normal-appearing cortical gray matter in patients with late RRMS or SPMS. 76 A novel PET ligand binding to a synaptic vesicle glycoprotein 2A (SV2A), 77, 78 [ 11 C]UCB-J, now enables imaging of synapses in the living human brain. 78 PET studies using this ligand will likely increase our understanding of the temporal development of gray matter pathology in MS and the association of white matter pathology to the developing neurodegeneration. The ability to image the synaptic density in vivo will likely have enormous potential in clarifying the mechanisms leading to progression of the disease.
Other potential PET imaging targets of neuroinflammation
There are several other potential PET imaging targets which have been used only in preclinical research or have shown potential also in clinical research but are still missing the final proof of their usability. We summarize shortly some of these targets and the pathology behind them in Table 4 .
Future perspectives TSPO-binding radioligands have formed the cornerstone of PET imaging of neuroinflammation, but the Involved in synaptic plasticity, neuronal survival, and neuroprotection. 79 Expressed mainly in neurons, microglia, and astrocytes. 80, 81 Reduced levels in neuroinflammatory and neurodegenerative diseases. 82 Activation of α7 in astrocytes inhibits NF-κB signaling 81 
2-[ 18 F]-fluoro-A85380
Reduced uptake in the thalamus and in the occipital cortex (human AD, in vitro)
Schmaljohann et al. 83 Reduced uptake in the caudate, putamen, and thalamus (human PD, in vitro)
Schmaljohann et al. 84 Increased binding in the acute phase of cerebral ischemia (MCAO rat, in vivo)
Martin et al. 80 [ Ohnishi et al. 93 Specific binding in neuroinflammatory areas (LPS-induced rat and AD mouse model, in vivo)
Shukuri et al. 94 No difference in binding between healthy subjects and patients (healthy and MCI/AD human subjects, in vivo)
Ohnishi et al. 95 Oxidative stress Mitochondria in activated macrophages, microglia, and astrocytes produce oxidizing agents contributing to tissue damage. 96 Tracer accumulation correlates with disease severity (human ALS, in vivo)
Ikawa et al. 104 [ 18 F]NOS Uptake correlates with myocardial tissue iNOS level (human OHT, in vivo)
Herrero et al. 105 Uptake correlates with endotoxin-induced iNOS in lungs (healthy humans, in vivo)
Huang et al. 106 (Continued) PET: positron emission tomography; AD: Alzheimer's disease; PD: Parkinson's disease; MCAO: cerebral ischemia rat model; NF-κB: nuclear factor-kappaB; BBB: blood-brain barrier; LPS: lipopolysaccharide; MCI: mild cognitive impairment; ROS: reactive oxygen species; MC-I: mitochondrial complex I; ALS: amyotrophic lateral sclerosis; OHT: orthotopic heart transplantation; iNOS: inducible nitric oxide synthase. 
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